A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

NCT07198633 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Prostate Cancer

Interventions

DRUG: QLC5508
DRUG: abiraterone acetate
DRUG: enzalutamide
DRUG: QLH12016

Sponsor

Qilu Pharmaceutical Co., Ltd.